Literature DB >> 24817116

T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling.

Man Li1, Pengyan Xia1, Ying Du2, Shengwu Liu1, Guanling Huang1, Jun Chen1, Honglian Zhang2, Ning Hou3, Xuan Cheng3, Luyu Zhou4, Peifeng Li4, Xiao Yang5, Zusen Fan6.   

Abstract

Natural killer (NK) cell activation is well orchestrated by a wide array of NK cell receptor repertoire. T-cell immunoglobulin and ITIM domain (TIGIT) receptor was recently defined as an inhibitory receptor that is expressed on NK cells and T cells. TIGIT receptor/poliovirus receptor (PVR) ligand engagement signaling inhibits cytotoxicity mediated by NK and CD8(+) T cells. However, it is unclear how TIGIT/PVR signaling regulates cytokine secretion in NK cells. Here we show that TIGIT/PVR engagement suppresses interferon-γ (IFN-γ) production of NK cells. TIGIT transgenic NK cells generate less IFN-γ undergoing TIGIT/PVR ligation. Moreover, TIGIT knock-out NK cells produce much more IFN-γ. TIGIT/PVR ligation signaling mediates suppression of IFN-γ production via the NF-κB pathway. We identified a novel adaptor β-arrestin 2 that associates with phosphorylated TIGIT for further recruitment of SHIP1 (SH2-containing inositol phosphatase 1) through the ITT-like motif. Importantly, SHIP1, but not other phosphatases, impairs the TNF receptor-associated factor 6 (TRAF6) autoubiquitination to abolish NF-κB activation, leading to suppression of IFN-γ production in NK cells.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Immunology; Innate Immunity; Interferon; Natural Killer Cells (NK Cells); Signaling

Mesh:

Substances:

Year:  2014        PMID: 24817116      PMCID: PMC4067199          DOI: 10.1074/jbc.M114.572420

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain.

Authors:  L Deng; C Wang; E Spencer; L Yang; A Braun; J You; C Slaughter; C Pickart; Z J Chen
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

Review 2.  Negative regulation of immunoreceptor signaling.

Authors:  André Veillette; Sylvain Latour; Dominique Davidson
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

Review 3.  Signaling to NF-kappaB.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Genes Dev       Date:  2004-09-15       Impact factor: 11.361

4.  Functional desensitization of the isolated beta-adrenergic receptor by the beta-adrenergic receptor kinase: potential role of an analog of the retinal protein arrestin (48-kDa protein).

Authors:  J L Benovic; H Kühn; I Weyand; J Codina; M G Caron; R J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

5.  NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors.

Authors:  Zusen Fan; Ping Yu; Yang Wang; Yugang Wang; May Lynne Fu; Wenhua Liu; Yonglian Sun; Yang-Xin Fu
Journal:  Blood       Date:  2005-10-13       Impact factor: 22.113

6.  Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation.

Authors:  Jia-Wang Wang; Julie M Howson; Tomar Ghansah; Caroline Desponts; John M Ninos; Sarah L May; Kim H T Nguyen; Noriko Toyama-Sorimachi; William G Kerr
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

7.  The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes.

Authors:  Lijun Sun; Li Deng; Chee-Kwee Ea; Zong-Ping Xia; Zhijian J Chen
Journal:  Mol Cell       Date:  2004-05-07       Impact factor: 17.970

8.  Identification of beta-arrestin2 as a G protein-coupled receptor-stimulated regulator of NF-kappaB pathways.

Authors:  Hua Gao; Yue Sun; Yalan Wu; Bing Luan; Yaya Wang; Bin Qu; Gang Pei
Journal:  Mol Cell       Date:  2004-05-07       Impact factor: 17.970

9.  Requirement for natural killer cell-produced interferon gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration.

Authors:  J S Orange; B Wang; C Terhorst; C A Biron
Journal:  J Exp Med       Date:  1995-10-01       Impact factor: 14.307

10.  Macrophages control the retention and trafficking of B lymphocytes in the splenic marginal zone.

Authors:  Mikael C I Karlsson; Rodolphe Guinamard; Silvia Bolland; Marko Sankala; Ralph M Steinman; Jeffrey V Ravetch
Journal:  J Exp Med       Date:  2003-07-21       Impact factor: 14.307

View more
  81 in total

1.  IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.

Authors:  Joe-Marc Chauvin; Mignane Ka; Ornella Pagliano; Carmine Menna; Quanquan Ding; Richelle DeBlasio; Cindy Sanders; Jiajie Hou; Xian-Yang Li; Soldano Ferrone; Diwakar Davar; John M Kirkwood; Robert J Johnston; Alan J Korman; Mark J Smyth; Hassane M Zarour
Journal:  Clin Cancer Res       Date:  2020-06-26       Impact factor: 12.531

2.  The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8+ T cell responses.

Authors:  Robert J Johnston; Xin Yu; Jane L Grogan
Journal:  Oncoimmunology       Date:  2015-05-27       Impact factor: 8.110

Review 3.  Checkpoint Inhibitors: Applications for Autoimmunity.

Authors:  Anna S Tocheva; Adam Mor
Journal:  Curr Allergy Asthma Rep       Date:  2017-09-27       Impact factor: 4.806

Review 4.  Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer.

Authors:  Nicholas Borcherding; Ryan Kolb; Jodi Gullicksrud; Praveen Vikas; Yuwen Zhu; Weizhou Zhang
Journal:  J Mol Biol       Date:  2018-05-22       Impact factor: 5.469

Review 5.  Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer.

Authors:  Hauke Stamm; Jasmin Wellbrock; Walter Fiedler
Journal:  Mamm Genome       Date:  2018-08-21       Impact factor: 2.957

Review 6.  Balancing natural killer cell activation through paired receptors.

Authors:  Ludovic Martinet; Mark J Smyth
Journal:  Nat Rev Immunol       Date:  2015-03-06       Impact factor: 53.106

7.  T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.

Authors:  Sarah E Josefsson; Kanutte Huse; Arne Kolstad; Klaus Beiske; Daniela Pende; Chloé B Steen; Else Marit Inderberg; Ole Christian Lingjærde; Bjørn Østenstad; Erlend B Smeland; Ronald Levy; Jonathan M Irish; June H Myklebust
Journal:  Clin Cancer Res       Date:  2017-12-07       Impact factor: 12.531

8.  Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients.

Authors:  Sun Min Lim; Min Hee Hong; Sang-Jun Ha; Daehee Hwang; Sehyun Chae; Yoon Woo Koh; Eun Chang Choi; Se-Heon Kim; Da-Hee Kim; Sun Och Yoon; Hye Ryun Kim
Journal:  J Cancer Res Clin Oncol       Date:  2021-02-22       Impact factor: 4.553

Review 9.  Tim-3, Lag-3, and TIGIT.

Authors:  Nicole Joller; Vijay K Kuchroo
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

Review 10.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

Authors:  Ana C Anderson; Nicole Joller; Vijay K Kuchroo
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.